OLMA

Several events have influenced OLMA's stock price over the past six months. Olema closed a public offering of common stock in November 2025, generating approximately $218.5 million. The stock reached a four-year high in December 2025 following an increased price target from Jefferies. In March 2026, the company reported its fourth quarter and full-year 2025 financial and operating results and announced preclinical data for Palazestrant and OP-3136 at the AACR Annual Meeting. Inducement grants were reported in April and May 2026. Olema announced plans to present initial clinical data for OP-3136 at the ASCO Annual Meeting and appointed Prakash Raman, Ph.D., to its Board of Directors in April 2026. The stock has increased by 157.55% from May 5, 2025, to May 1, 2026, and 226.8% over the past 12 months, with a six-month increase of 81.71%. However, year-to-date in 2026, the stock has decreased by 40.4%. The stock's 52-week high was $36.26 and its low was $3.89.